COVID-19 Vaccine
New Delhi/UNI: The Centre will procure 30 crore units of COVID-19 vaccine from Hyderabad-based firm Biological-E, an official statement said here on Thursday.
As per the deal, the vaccine doses will be manufactured and stockpiled by the manufacturer from August-December 2021.
The Union Ministry of Health would be making an advance payment of Rs 1,500 crore to the firm.
Currently, the vaccine of Biological-E is undergoing Phase-3 clinical trials. The vaccine being developed by Biological-E is a RBD protein sub-unit vaccine and is likely to be available in the next few months, the statement read.
The proposal of M/s Biological-E was examined and recommended for approval after due diligence by the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC).
'The arrangement with M/s Biological-E is part of the wider endeavour of the Government of India to encourage indigenous vaccine manufacturers by providing them support in Research & Development (R&D) and also financial support,' the Ministry said.
The Biological-E COVID Vaccine candidate has been supported by the Centre from Preclinical stage to Phase-3 studies. Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 cr but has also partnered with Biological-E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
